Andrea Wang-Gillam
Overview
Explore the profile of Andrea Wang-Gillam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
6868
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou X, Yang X, Grinshpun B, Taylor A, Strong L, Dasari A, et al.
J Clin Pharmacol
. 2025 Feb;
PMID: 39969131
Fruquintinib is a selective, oral tyrosine kinase inhibitor of all three vascular endothelial growth factor receptors 1, 2, and 3, which is approved for patients with previously treated metastatic colorectal...
2.
Shi Y, Fang J, Xing L, Yao Y, Zhang J, Liu L, et al.
Nat Med
. 2025 Jan;
PMID: 39762419
Glecirasib (JAB-21822) is a new covalent oral KRAS-G12C inhibitor. This multicenter, single-arm phase 2b study assessed the efficacy and safety of glecirasib administered orally at 800 mg daily in patients...
3.
Zhang X, Goedegebuure S, Chen M, Mishra R, Zhang F, Yu Y, et al.
Genome Med
. 2024 Nov;
16(1):131.
PMID: 39538331
Background: Neoantigen vaccines can induce or enhance highly specific antitumor immune responses with minimal risk of autoimmunity. We have developed a neoantigen DNA vaccine platform capable of efficiently presenting both...
4.
Klomp J, Klomp J, Stalnecker C, Bryant K, Edwards A, Drizyte-Miller K, et al.
Science
. 2024 Jun;
384(6700):eadk0775.
PMID: 38843331
How the oncogene drives cancer growth remains poorly understood. Therefore, we established a systemwide portrait of KRAS- and extracellular signal-regulated kinase (ERK)-dependent gene transcription in KRAS-mutant cancer to delineate the...
5.
Bulle A, Liu P, Seehra K, Bansod S, Chen Y, Zahra K, et al.
Nat Commun
. 2024 Mar;
15(1):2503.
PMID: 38509064
Targeting the mitogen-activated protein kinase (MAPK) cascade in pancreatic ductal adenocarcinoma (PDAC) remains clinically unsuccessful. We aim to develop a MAPK inhibitor-based therapeutic combination with strong preclinical efficacy. Utilizing a...
6.
Sohal D, Boutin R, Lenchik L, Kim J, Beg M, Wang-Gillam A, et al.
J Gastrointest Surg
. 2024 Mar;
28(3):232-235.
PMID: 38445914
Background: Sarcopenic obesity and muscle attenuation have been associated with survival in patients with borderline resectable and advanced pancreatic ductal adenocarcinoma (PDA); however, these relationships are unknown for patients with...
7.
Barzi A, Weipert C, Espenschied C, Raymond V, Wang-Gillam A, Nezami M, et al.
Front Oncol
. 2024 Feb;
14:1339302.
PMID: 38406801
Purpose: Despite accumulating data regarding the genomic landscape of pancreatic ductal adenocarcinoma (PDAC), olaparib is the only biomarker-driven FDA-approved targeted therapy with a PDAC-specific approval. Treating (HER2)-amplified PDAC with anti-HER2...
8.
Wattenberg M, Colby S, Garrido-Laguna I, Xue Y, Chang R, Delman D, et al.
Gastroenterology
. 2024 Jan;
166(6):1114-1129.
PMID: 38244727
Background & Aims: Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease characterized by a spatially heterogeneous tumor microenvironment. Within the PDA microenvironment, cells organize into communities where cell fate...
9.
Wang-Gillam A, Lim K, McWilliams R, Suresh R, Lockhart A, Brown A, et al.
Clin Cancer Res
. 2023 Nov;
29(22):4698.
PMID: 37960920
No abstract available.
10.
Leidner R, Conlon K, McNeel D, Wang-Gillam A, Gupta S, Wesolowski R, et al.
J Immunother Cancer
. 2023 Oct;
11(10).
PMID: 37907221
Background: Preclinically, interleukin-15 (IL-15) monotherapy promotes antitumor immune responses, which are enhanced when IL-15 is used in combination with immune checkpoint inhibitors (ICIs). This first-in-human study investigated NIZ985, a recombinant...